| Leishvaccine | Whole-killed promastigotes of L. amazonensis | BCG (Bacillus Calmette Guerin); CD4+, CD8+, B cell activation |
| ALMϼ (autoclaved-killed L. major) | Autoclave-killed L. major | BCG; T cell activation |
| Leishmune | FML (fucose-mannose ligand) | Saponin; T cell activation |
| CaniLeish | LiESP (L. infantum excreted-secreted protein) | Saponin; induction of Th1 cell |
| GALMα (gentamycin-attenuated L. major) | GALM | T and B cell activation |
| LEISH-F1 | TSA + LmSTI1 + LeIF | MPL-SE (monophosphoryl lipid A-stable emulsion); T cell activation |
| LEISH-F2 | LEISH-F2, designed from LEISH-F1 | MPL-SE; T cell activation |
| LEISH-F3 | NH + SMT (nucleoside hydrolase; sterol 24-c-methyltransferase) | GLA (glucopyranosyl lipid A)-SE; T cell activation |
| Leish-Tec | L. donovani A2 protein | Saponin; T cell activation |
| SMTγ + NHμ | NH + SMT | GLA-SE; T cell activation |
| ChAd63-KH | KMP-11 + HASPB (kinetoplastid membrane protein 11; hydrophilic acylated surface protein B) | Broad CD8+ T cell activation |